The board of directors of Ocumension Therapeutics announced that OT-502 (dexamethasone implant), a new drug for the treatment of postoperative inflammation indication, has completed the enrollment of a total of 300 patients for the phase III clinical trial in China on November 29, 2023. OT-502 (dexAMethasone implant) is a single-dose, sustained-release solution of dexamethasone, a corticosteroid, for the treatment of postoperativeinflamm. To date, OT-502 is the first and only single-dose, sustained- release intracameral steroid for the treatment of postoperative inflammatory that was approved by the United States Food and Drug Administration.

The Group is developing OT-502 as a potential first-in-class treatment for postoperative inflammation associated with cataract surgery in China. The phase III clinical trial of OT-502 is designed to be a randomized, double-masked, placebo-controlled, parallel-group, multi-center clinical and pharmacokinetic study to evaluate the efficacy and safety of 9% dexamethasone implant in the treatment of postoperative inflammation.